Expression of the gene encoding blood coagulation factor VIII without domain B in E. coli bacterial expression system.

Autor:	Mazurkiewicz-Pisarek A; Centre for Advanced Materials and Technologies, Warsaw University of Technology, Warszawa, Poland., Mazurkiewicz A; Centre for Advanced Materials and Technologies, Warsaw University of Technology, Warszawa, Poland., Mikiewicz D; Science4Beauty LLC, Warszawa, Poland., Baran P; Military Institute of Armament Technology, Zielonka, Poland., Ciach T; University of Technology, Faculty of Chemical and Process Engineering, Warszawa, Poland.
Jazyk:	angličtina
Zdroj:	Biotechnologia [BioTechnologia (Pozn)] 2023 Sep 25; Vol. 104 (3), pp. 247-262. Date of Electronic Publication: 2023 Sep 25 (Print Publication: 2023).
DOI:	10.5114/bta.2023.130728
Abstrakt:	In this article, we have demonstrated the feasibility of generating an active form of recombinant blood coagulation factor VIII using an E. coli bacterial expression system as a potential treatment for hemophilia type A. Factor VIII (FVIII), an essential blood coagulation protein, is a key component of the fluid phase blood coagulation system. So far, all available recombinant FVIII formulations have been produced using eukaryotic expression systems. Mammalian cells can produce catalytically active proteins with all the necessary posttranslational modifications. However, cultivating such cells is time-consuming and highly expensive, and the amount of the obtained product is usually low. In contrast to eukaryotic cells, bacterial culture is inexpensive and allows the acquisition of large quantities of recombinant proteins in a short time. With this study, we aimed to obtain recombinant blood coagulation factor VIII using the E. coli bacterial expression system, a method not previously explored for this purpose. Our research encompasses the synthesis of blood coagulation factor VIII and its expression in a prokaryotic system. To achieve this, we constructed a prokaryotic expression vector containing a synthetic factor VIII gene, which was then used for the transformation of an E. coli bacterial strain. The protein expression was confirmed by mass spectrometry, and we assessed the stability of the gene construct while determining the optimal growth conditions. The production of blood coagulation factor VIII by the E. coli bacterial strain was carried out on a quarter-technical scale. We established the conditions for isolation, denaturation, and renaturation of the protein, and subsequently confirmed the activity of FVIII. Competing Interests: The authors declare that they have no competing interests. (© 2023 Institute of Bioorganic Chemistry, Polish Academy of Sciences.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu